A groundbreaking discovery has emerged from an unexpected source: a shingles vaccination program in Wales. This program, initiated in 2013, has unveiled a potential game-changer in the fight against dementia. The vaccine, originally designed to combat shingles, has shown remarkable results in reducing the risk of mild cognitive impairment and even slowing the progression of dementia in those already diagnosed.
We first reported on this exciting development back in April, when initial findings were published in Nature. Now, a new study has revealed an even more promising aspect: the vaccine is linked to a reduced risk of death from dementia in patients with an existing diagnosis.
This latest research, conducted by an international team of scientists, adds to a growing body of evidence suggesting that targeting viruses that affect the nervous system, such as the varicella zoster virus (which causes shingles), could be a key strategy in preventing and managing dementia.
"The implications of this finding are significant, as the vaccine is safe, affordable, and already widely available," says Haroon Ahmed, an epidemiologist from Cardiff University. "However, more research is needed to fully understand the protective effect of the vaccine and how it works."
The Welsh vaccination program, implemented over a decade ago by the UK National Health Service, provided a unique opportunity for researchers. To allocate vaccines fairly, the program offered the vaccine to those aged 79, while those aged 80 were not eligible. This quirk created two very similar groups, differing by just one year in age, allowing researchers to study the effects of the vaccine with minimal influence from other factors that impact dementia risk, such as education or medical history.
Among the 14,350 individuals diagnosed with dementia prior to the vaccine program, approximately half passed away from the condition within nine years. Remarkably, being vaccinated against shingles made this outcome nearly 30% less likely, according to the analysis, indicating a substantial level of protection.
The researchers also found that vaccinated participants were less likely to develop mild cognitive impairment, a common precursor to dementia, and those who did develop it progressed more slowly. Combined with previous findings that the vaccine reduces the overall risk of dementia, these results are incredibly encouraging.
"What's most exciting is that the shingles vaccine appears to have both preventive and therapeutic benefits for those with dementia," says Pascal Geldsetzer, a biomedical scientist from Stanford University.
While the design of the Welsh program provides valuable insights, the data doesn't conclusively prove a direct cause-and-effect relationship. However, it highlights a significant connection that warrants further investigation.
One of the next steps is to uncover why the shingles vaccine has this impact on dementia. It could be related to mechanisms in the nervous or immune systems. For instance, viruses affecting the nervous system have been linked to the toxic protein buildup seen in Alzheimer's disease in animal models.
Future studies could explore larger and more diverse populations, including investigating the latest shingles vaccine, which is an improved version of the one used in Wales in 2013.
"Investing resources into understanding these pathways could lead to groundbreaking advancements in treatment and prevention," Geldsetzer emphasizes.
This research has been published in Cell, shedding new light on the potential of an existing vaccine to revolutionize dementia care.
